GlassScriptPhysician profile
Matthew James Suggs
NPI 1326543596
$827.37
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $197 · 2021: $333 · 2022: $297.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $191.29 | 2021-2022 | |
| Alkermes, INC. | $183.15 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $119.14 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.69 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $84.05 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $50.91 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $32.26 | 2022 | |
| Abbvie INC. | $26.83 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.23 | 2021 | |
| Intuitive Surgical, INC. | $6.82 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Suggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.